risperidone has been researched along with Pain in 11 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Injection site pain, other skin reactions and patient satisfaction with treatment were assessed in two large, multicentre studies of long-acting injectable risperidone (Risperdal CONSTA, Janssen Pharmaceutica Products, Titusville, New Jersey, USA), the first available long-acting atypical antipsychotic agent." | 9.11 | Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. ( Bossie, CA; Jarboe, K; Lasser, R; Lindenmayer, JP; Mehnert, A; Zhu, Y, 2005) |
| "The ketamine (ket) model reflects features of schizophrenia as well as secondary symptoms such as altered pain sensitivity." | 7.75 | Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia. ( Becker, A; Grecksch, G; Hiemke, C; Ladstaetter, E; Schmitt, U; Zernig, G, 2009) |
| " Three nursing-home residents who suffered from multiple somatic disorders and dementia, two men aged 78 and 76 years respectively and a woman aged 72 years, developed neuroleptic malignant syndrome following the use of risperidone." | 7.72 | [Neuroleptic malignant syndrome in users of risperidone]. ( de Jonghe-Rouleau, AP; Gerritsen, AA; Stienstra-Liem, LH, 2004) |
| " Overall, 63 (94%) patients experienced at least one treatment-emergent adverse event (TEAE)." | 6.87 | A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia. ( Anta, L; Ayani, I; Gutierro, I; Litman, RE; Llaudó, J; Martínez, J, 2018) |
| " Antinociception was assessed by dose-response curves to paracetamol and meloxicam before and after the i." | 5.72 | Risperidone in analgesia induced by paracetamol and meloxicam in experimental pain. ( Miranda, HF; Noriega, V; Prieto, JC; Sierralta, F; Sotomayor-Zárate, R, 2022) |
| "Previous studies showed clinical benefit of risperidone long-acting injection in the treatment of schizophrenia." | 5.12 | Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. ( Bai, YM; Chang, WH; Chen, JY; Hung, CH; Kuo Lin, W; Ting Chen, T; Wu, B, 2007) |
| " Injection site pain, other skin reactions and patient satisfaction with treatment were assessed in two large, multicentre studies of long-acting injectable risperidone (Risperdal CONSTA, Janssen Pharmaceutica Products, Titusville, New Jersey, USA), the first available long-acting atypical antipsychotic agent." | 5.11 | Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. ( Bossie, CA; Jarboe, K; Lasser, R; Lindenmayer, JP; Mehnert, A; Zhu, Y, 2005) |
| "The ketamine (ket) model reflects features of schizophrenia as well as secondary symptoms such as altered pain sensitivity." | 3.75 | Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia. ( Becker, A; Grecksch, G; Hiemke, C; Ladstaetter, E; Schmitt, U; Zernig, G, 2009) |
| " Three nursing-home residents who suffered from multiple somatic disorders and dementia, two men aged 78 and 76 years respectively and a woman aged 72 years, developed neuroleptic malignant syndrome following the use of risperidone." | 3.72 | [Neuroleptic malignant syndrome in users of risperidone]. ( de Jonghe-Rouleau, AP; Gerritsen, AA; Stienstra-Liem, LH, 2004) |
| " Overall, 63 (94%) patients experienced at least one treatment-emergent adverse event (TEAE)." | 2.87 | A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia. ( Anta, L; Ayani, I; Gutierro, I; Litman, RE; Llaudó, J; Martínez, J, 2018) |
| "RLAI and OP show good short- and long-term safety when treating patients with schizophrenia, with uncommon discontinuation due to adverse effects." | 2.46 | Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review. ( Cañas, F; Möller, HJ, 2010) |
| " Antinociception was assessed by dose-response curves to paracetamol and meloxicam before and after the i." | 1.72 | Risperidone in analgesia induced by paracetamol and meloxicam in experimental pain. ( Miranda, HF; Noriega, V; Prieto, JC; Sierralta, F; Sotomayor-Zárate, R, 2022) |
| "Risperidone is a neuroleptic with a potent dopamine D2 and serotonin 5-HT2 receptor-blocking activity as well as a high affinity for adrenergic and histamine H1 receptors." | 1.62 | The Opioid Interactions of the Antipsychotic Medications Risperidone and Amisulpride in Mice and Their Potential Use in the Treatment of Other Non-Psychotic Medical Conditions. ( Pick, CG; Schreiber, S, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Wells, MM | 1 |
| Tillman, TS | 1 |
| Mowrey, DD | 1 |
| Sun, T | 1 |
| Xu, Y | 1 |
| Tang, P | 1 |
| Miranda, HF | 1 |
| Noriega, V | 1 |
| Sierralta, F | 1 |
| Sotomayor-Zárate, R | 1 |
| Prieto, JC | 1 |
| Schreiber, S | 1 |
| Pick, CG | 1 |
| Anta, L | 1 |
| Llaudó, J | 1 |
| Ayani, I | 1 |
| Martínez, J | 1 |
| Litman, RE | 1 |
| Gutierro, I | 1 |
| Becker, A | 1 |
| Grecksch, G | 1 |
| Zernig, G | 1 |
| Ladstaetter, E | 1 |
| Hiemke, C | 1 |
| Schmitt, U | 1 |
| Cañas, F | 1 |
| Möller, HJ | 1 |
| Gerritsen, AA | 1 |
| de Jonghe-Rouleau, AP | 1 |
| Stienstra-Liem, LH | 1 |
| Pinninti, NR | 1 |
| Mago, R | 1 |
| Lindenmayer, JP | 1 |
| Jarboe, K | 1 |
| Bossie, CA | 1 |
| Zhu, Y | 1 |
| Mehnert, A | 1 |
| Lasser, R | 1 |
| Reiss, JP | 1 |
| Sam, D | 1 |
| Sareen, J | 1 |
| Bai, YM | 1 |
| Ting Chen, T | 1 |
| Chen, JY | 1 |
| Chang, WH | 1 |
| Wu, B | 1 |
| Hung, CH | 1 |
| Kuo Lin, W | 1 |
1 review available for risperidone and Pain
| Article | Year |
|---|---|
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.
Topics: Administration, Oral; Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Dyslipidem | 2010 |
3 trials available for risperidone and Pain
| Article | Year |
|---|---|
A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Adm | 2018 |
Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone.
Topics: Adult; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Injections, Subcutaneous; M | 2005 |
Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study.
Topics: Administration, Oral; Adult; Aged; Female; Humans; Injections; Male; Middle Aged; Pain; Pain Measure | 2007 |
7 other studies available for risperidone and Pain
| Article | Year |
|---|---|
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
Topics: Analgesics, Non-Narcotic; Animals; Binding Sites; Cannabinoids; Drug Evaluation, Preclinical; Female | 2015 |
Risperidone in analgesia induced by paracetamol and meloxicam in experimental pain.
Topics: Acetaminophen; Analgesia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Meloxicam; Mice; Pain; R | 2022 |
The Opioid Interactions of the Antipsychotic Medications Risperidone and Amisulpride in Mice and Their Potential Use in the Treatment of Other Non-Psychotic Medical Conditions.
Topics: Amisulpride; Analgesics, Opioid; Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Dr | 2021 |
Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia.
Topics: Analgesics, Opioid; Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Electric Stimul | 2009 |
[Neuroleptic malignant syndrome in users of risperidone].
Topics: Aged; Antipsychotic Agents; Dementia; Fatal Outcome; Female; Fever; Humans; Male; Neuroleptic Malign | 2004 |
Injection site pain with long-acting risperidone.
Topics: Analgesia; Antipsychotic Agents; Delayed-Action Preparations; Drug Administration Schedule; Drug Lab | 2005 |
Psychosis in multiple sclerosis associated with left temporal lobe lesions on serial MRI scans.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delusions; Excitatory Amino Acid Antagonists; Female; | 2006 |